Sermorelin vs Tesamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | Sermorelin | Tesamorelin |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 2 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 8–12 weeks | 8–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
What They Have in Common
Sermorelin, Tesamorelin are both commonly used for:
Key Differences
Unique to Sermorelin:
Which Has Stronger Evidence?
- Fat Loss: Tesamorelin has stronger research support.
| Goal | Sermorelin | Tesamorelin |
|---|---|---|
| Muscle Growth | medium | medium |
| Fat Loss | medium | high |
Key Studies
Sermorelin
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine, 2021
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging, 2006
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999
Tesamorelin
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
BMJ open, 2026
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
The Journal of infectious diseases, 2025
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
AIDS (London, England), 2024
Ready to Learn More?
Looking for trusted sources?